Abstract:Objective: To investigate the efficacy of laparoscopic hyperthermic intraperitoneal perfusion chemotherapy combined with intraperitoneal and systemic chemotherapy (HIPEC-IP-IV) in the treatment of peritoneal metastases from gastric cancer (GCPM). Methods: This was a descriptive case series study. Indications for HIPEC-IP-IV treatment include: (1) pathologically confirmed gastric or esophagogastric junction adenocarcinoma; (2) age 20-85 years; (3) peritoneal metastases as the sole form of Stage IV disease, confirmed by computed tomography, laparoscopic exploration, ascites or peritoneal lavage fluid cytology; and (4) Eastern Cooperative Oncology Group performance status 0-1. Contraindications include: (1) routine blood tests, liver and renal function, and electrocardiogram showing no contraindications to chemotherapy; (2) no serious cardiopulmonary dysfunction; and (3) no intestinal obstruction or peritoneal adhesions. According to the above criteria, data of patients with GCPM who had undergone laparoscopic exploration and HIPEC from June 2015 to March 2021 in the Peking University Cancer Hospital Gastrointestinal Center were analyzed, after excluding those who had received antitumor medical or surgical treatment. Two weeks after laparoscopic exploration and HIPEC, the patients received intraperitoneal and systemic chemotherapy. They were evaluated every two to four cycles. Surgery was considered if the treatment was effective, as shown by achieving stable disease or a partial or complete response and negative cytology. The primary outcomes were surgical conversion rate, R0 resection rate, and overall survival. Results: Sixty-nine previously untreated patients with GCPM had undergone HIPEC-IP-IV, including 43 men and 26 women; with a median age of 59 (24-83) years. The median PCI was 10 (1-39). Thirteen patients (18.8%) underwent surgery after HIPEC-IP-IV, R0 being achieved in nine of them (13.0%). The median overall survival (OS) was 16.1 months. The median OS of patients with massive or moderate ascites and little or no ascites were 6.6 and 17.9 months, respectively (P<0.001). The median OS of patients who had undergone R0 surgery, non-R0 surgery, and no surgery were 32.8, 8.0, and 14.9 months, respectively (P=0.007). Conclusions: HIPEC-IP-IV is a feasible treatment protocol for GCPM. Patients with massive or moderate ascites have a poor prognosis. Candidates for surgery should be selected carefully from those in whom treatment has been effective and R0 should be aimed for.

Hyperthermic Intraperitoneal Perfusion Chemotherapy and Response Evaluation in Patients with Gastric Cancer and Malignant Ascites.

Analysis of intraperitoneal hyperthermic chemoperfusion combined with interleukin-2 in the treatment of malignant ascites

Correlation Of Beta-Tubulin Iii And Ercc1 Mrna Expression To Chemotherapy Outcome Of Gastric Cancer Patients With Malignant Ascites

[Study of Introperitoneal Hyperthermic Perfusion Chemotherapy Combined with Systemic Neoadjuvent Chemotherapy in Treatment of Gastric Cancer Patients with Peritoneal Carcinomatosis].

Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia to cure advanced ovarian cancer

[In Vitro Chemo-Sensitivity MTT Assay Guided Intraperitoneal Chemotherapy for Malignant Ascites].

Intraperitoneal Perfusion Chemotherapy And Whole Abdominal Hyperthermia Using External Radiofrequency Following Radical D2 Resection For Treatment Of Advanced Gastric Cancer

Efficacy and safety of hyperthermic intraperitoneal chemotherapy combined with systemic chemotherapy in treatment of gastric cancer with malignant ascites:A Meta－analysis

Hyperthermic intrathoracic/intraperitoneal chemotherapy versus conventional intrapleural/intraperitoneal chemotherapy for the malignant effusion: a multi-center randomized clinical trial

Neoadjuvant Systemic and Hyperthermic Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery for Gastric Cancer Patients with Limited Peritoneal Metastasis: a Prospective Cohort Study

Clinical Study of Cisplatin Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Docetaxel, 5-Flourouracil and Leucovorin Intravenous Chemotherapy for the Treatment of Advanced-Stage Gastric Carcinoma.

Effects of Laparoscopic Hyperthermic Intraperitoneal Perfusion Chemotherapy Combined with Intraperitoneal and Systemic Chemotherapy Treatment in Patients with Untreated Gastric Cancer with Peritoneal Metastasis

Hyperthermia combined with intracavitary injection of drug for malignant pleural effusion

Effect of domestic paclitaxel combined with external high frequency thermotherapy on malignant peritoneal effusion

Cytoreductive Surgery plus Hyperthermic Intra-peritoneal Chemotherapy for Peritoneal Carcinomatosis from Gastric Cancer

P-0138 Transcatheter Arterial Chemoembolization in the Treatments for Unresectable Intrahepatic Cholangiocarcinoma

Surgical resection with hyperthermic intraperitoneal chemotherapy for gastric cancer patients with peritoneal dissemination.

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies

Observation on intraperitoneal chemotherapy combined with whole body hyperthermia after palliative surgery for advanced gastric carcinoma

[Efficacy of Intraoperative Hypotonic Peritoneal Chemo-Hyperthermia Combined with Early Postoperative Intraperitoneal Chemotherapy on Gastric Cancer].

Whole-Body Hyperthermia Combined With Hyperthermic Intraperitoneal Chemotherapy For The Treatment Of Stage Iv Advanced Gastric Cancer